As an international start-up competition, Falling Walls Venture showcases the most promising research-based initiatives from upcoming science-based entrepreneurs who are nominated by academic institutions from around the globe. The 25 best emerging companies are invited to pitch their pioneering ideas and business models in front of a high-calibre jury and audience in Berlin. In a Joint Award Ceremony on 7 November with Falling Walls Lab (Emerging Talents) and Falling Walls Engage (Science Engagement), the winner will be dubbed the “Falling Walls Breakthrough of the Year in the Science Start-ups category”.
On 9 November, the recipient of this award will be invited to present again on the grand stage of the Falling Walls Science Summit, together with the Awardees of the Falling Walls Science Breakthrough of the Year in the other nine categories.
The Winners in the Health Solutions Cluster of Falling Walls Venture will present groundbreaking projects that unlock the knowledge from within research labs around the world, to help tackle global health problems and improve daily quality of life.
Who will pitch?
2. Ribbon Biolabs
4. GrayMatters Health
6. Axolotl Biosciences
Born in the US and raised in Switzerland, cellvie is seeking to bring about a new treatment modality: Therapeutic Mitochondria Transplantation, which was conceived at Harvard Medical School. It involves the transfer of viable mitochondria into cells where the energy metabolism has been compromised or is in need of amplification.
cellvie is pursuing this technology as a platform, seeking to establish the mitochondria’s potential in ischemia-reperfusion injury, gene therapy and aging related degeneration. The first application will be in heart-attack patients, an indication where cellvie’s co-founder showed the potential for a 60%-reduction in muscle damage in a corresponding large animal study. If the team succeeds, their work may spur a whole new industry around mitochondria as a category of medicines.
Ribbon Biolabs is a biotech startup pursuing a new technology for the automated synthesis of long DNA molecules. It’s our ambition to act as a breakthrough-enabler for biotechnology and biopharma by replacing classic recombinant technologies for DNA synthesis.
Current DNA technologies are limited to high-throughput production of small DNA molecules, while the assembly of larger constructs still relies on slower and expensive cloning techniques. Ribbon Biolabs has developed a drastically different technology, enabling the automated high-throughput production of DNA molecules of unprecedented lengths (up to 100K bp against 2k-3k bp capability of current de novo DNA synthesis technologies). This will not only save time and costs for discovery and production in biopharma but ultimately allow for the realization of more ambitious R&D projects, new product development and technologies.
The final beneficiaries of Ribbon Biolabs’ technology are the patients in need, who will gain access to more and better solutions for different diseases such as diverse types of cancers, congenital metabolic disorders and mass-population demanding preventive biologics (e.g. vaccines).
Biotx.ai is the first company to go from biobank data all the way to a clinical trial phase 2b. Purely computationally, they found a potential COVID-19 treatment via what they call synthetic clinical trials, without a single wet lab experiment, for a fraction of the cost and time usually needed. In addition to the drug in phase 2b, their talented team also has molecules in several disease areas in pre-clinical and phase 1.
GrayMatters is developing a new mental-health therapy using and targeting biomarkers of brain regions and processes associated with emotional dysregulation, rather than treating the symptoms or behaviors.
Using machine learning, we fuse Electroencephalogram (EEG) and 3D fMRI (functional Magnetic Resonance Imaging) data, to create an Electrical-Fingerprint (EFP) of brain-mechanism-specific biomarkers. The Amygdala is the center of emotion regulation in the brain. Our Amygdala-EFP biomarker is used in our Prism system, which is now under clinical evaluation in five sites across the United States and Israel, to treat Post Traumatic Stress Disorder (PTSD) as an adjunct to standard of care. During treatment, patients use self-neuromodulation techniques to regulate their amygdala-EFP biomarker while interacting with an Audio-Visual interface.
The company plans to evaluate the clinical efficacy of Prism for additional mental disorder indications like Depression, ADHD, Anxiety, and OCD.
ArgenTAG is building a next-generation single-cell sequencing technology. They developed a novel approach for researchers, biotech and pharma companies to reveal the complete RNA landscape of cells in a cost-effective and scalable way. It’s based on a device-free protocol and a proprietary barcoding technology for long-read DNA sequencers.
The company is located in New York City (US) where they are running collaborations with well-known academic institutions and biotech companies. They also have a R&D center in Rosario (Argentina). They recently completed IndieBio, #1 biotech acceleration program, and gained SOSV, DraperU Ventures and Grid Exponential as investors.
Axolotl Biosciences, an award-winning start-up spun out of the Willerth lab at the University of Victoria, provides turn-key reagents such as functional bioinks, 3D tissue models, and consulting services in the field of 3D bioprinting. Our goal is to improve human health through novel 3D printing technologies.
Our initial product – TissuePrint – is a highly optimized bioink formulation for 3D printing human tissues using stem cells that is currently available for purchase through our website. We are currently beta testing our second product – BrainPrint – a novel neurobioink capable of printing delicate neural stem cells while maintaining a high-level cell viability and function.
Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome as system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer noninvasively. Elypta is advancing a broad clinical program with core indications in multi-cancer early detection and surveillance of recurrence in renal cell carcinoma.
Tubulis develops antibody-drug conjugates (ADCs) for the targeted therapy of cancer diseases with the aim of opening up new avenues in the treatment of tumors and providing patients with safe and effective ADCs. The basis for this is a proprietary platform consisting of novel drug chemistry, conjugation technologies and innovative target biology. This platform has been shown to address the core challenges of ADCs, enabling more effective and less toxic therapies.
Recently, the company closed its Series B financing round of EUR 60 million. This will be used to further develop and clinically validate Tubulis’ proprietary pipeline for the treatment of liquid and solid tumors.
Neuronostics is a multi-award-winning start-up developing solutions for diagnosis and management of neurological conditions. Neuronostics technology uses advanced mathematical modelling and machine learning tools to create digital biomarkers that reveal the risk of neurological conditions from routinely acquired clinical data.
Spun out of the University of Exeter in 2018, its first focus is on epilepsy: a condition affecting 65 million globally. Epilepsy is hard to diagnose, easy to misdiagnose and difficult to treat. It takes a year on average to confirm a case. Misdiagnosis rates can exceed 30%. 50% of people with epilepsy are not seizure free a year post-treatment. Addressing these challenges Neuronostics’ patented BioEP marker reveals the risk of future seizures from just a few seconds of apparently normal EEG. Published studies have shown that BioEP matches current clinical practice. Recent work has shown that changes in the BioEP score over time reveals medication response.
A radically new therapeutic approach that aims to improve the quality of life of cancer patients and beyond: PROSION Therapeutics is a biotech & drug development company with a proprietary “LEGO-like” platform, aiming to address highly unmet medical needs by unlocking undruggable protein targets.
Starting off in oncology, our mission is to develop new drugs against hard-to-treat diseases with the vision to directly benefit patients’ survival and overall quality of life. As of 2022, PROSION is backed by the European Commission through their prestigious EIC Accelerator.